Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class
摘要:
Substituted heterocyclic analogs in the Flosulide class were investigated as potential selective . 6-(4-Ethyl-2-thiazolylthio)-5-methanesulfonamido-3H-isobenzofuran-1-one 14 was found to be the optimal compound in the series with superior in vitro and in vivo activities. (C) 1999 Elsevier Science Ltd. All rights reserved.
Substituted heterocyclic analogs as selective COX-2 inhibitors in the flosulide class
摘要:
Substituted heterocyclic analogs in the Flosulide class were investigated as potential selective . 6-(4-Ethyl-2-thiazolylthio)-5-methanesulfonamido-3H-isobenzofuran-1-one 14 was found to be the optimal compound in the series with superior in vitro and in vivo activities. (C) 1999 Elsevier Science Ltd. All rights reserved.
5-Methanesulfonamido-3H-isobenzofuran-1-ones as inhibitors of
申请人:Merck Frosst Canada, Inc.
公开号:US05968958A1
公开(公告)日:1999-10-19
The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
[EN] 5-METHANESULFONAMIDO-3H-ISOBENZOFURAN-1-ONES AS INHIBITORS OF CYCLOOXYGENASE-2<br/>[FR] 5-METHANESULFONAMIDO-3H-ISOBENZOFURAN-1-ONES UTILISES COMME INHIBITEURS DE CYCLOOXYGENASE-2
申请人:MERCK FROSST CANADA INC.
公开号:WO1996023786A1
公开(公告)日:1996-08-08
(EN) The invention encompasses the novel compound of formula (I) as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of formula (I). The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).(FR) L'invention se rapporte aux nouveaux composés de la formule (I) ainsi qu'à un procédé de traitement des maladies induites par la cyclooxygénase-2, ce procédé consistant à administrer à un patient nécessitant ce type de traitement une quantité non toxique, thérapeutiquement efficace, d'un composé de la formule (I). L'invention se rapporte également à certaines compositions pharmaceutiques utilisées dans le traitement des maladies induites par la cyclooxygénase-2 comprenant les composés de la formule (I).
Substituted heterocyclic analogs in the Flosulide class were investigated as potential selective . 6-(4-Ethyl-2-thiazolylthio)-5-methanesulfonamido-3H-isobenzofuran-1-one 14 was found to be the optimal compound in the series with superior in vitro and in vivo activities. (C) 1999 Elsevier Science Ltd. All rights reserved.